Company / SG&A Expense
IQVIA SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$2.0B
FY2025
5-year range
$1.7B / $2.1B
FY2021-FY2025
Trend
+0.4%
vs FY2024
Sector context
#28 of 158
Health Care
What the data says
IQVIA's sg&a expense of $2.0B is higher than 82% of companies in the Health Care sector (FY2025). SG&A Expense has fluctuated over the past 10 years, ranging from $1.0B in FY2018 to $2.1B in FY2023.
Based on SEC 10-K filings.
$2.0B in FY2025 with a 5-year CAGR of +3.1%. Top quartile in the Health Care sector.
Improved from $2.1B to $2.0B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +3.8%
- 5-Year CAGR
- +3.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 158This company $2.0B Sector average $175.9B
▼
-98.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +3.1%, indicating consistent growth.
- In FY2025, sg&a expense increased 0.4% year-over-year.
- Ranks #28 out of 158 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 1.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 20.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.0B | +0.4% |
| FY2024 | $2.0B | -3.0% |
| FY2023 | $2.1B | +14.8% |
| FY2022 | $1.8B | +3.2% |
| FY2021 | $1.7B | +1.0% |
| FY2020 | $1.7B | +5.8% |
| FY2019 | $1.6B | +59.6% |
| FY2018 | $1.0B | -37.4% |
| FY2017 | $1.6B | +59.6% |
| FY2016 | $1.0B | +24.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026